Merck MRK announced better-than-expected fourth-quarter 2025 results earlier this month. The company beat estimates for both ...

Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.

Sanofi has replaced chief executive Paul Hudson with the head of German drugmaker Merck KGaA, after the French drugmaker ...

Advocacy groups from 30 countries are urging Merck to create a global access strategy for its once-a-month HIV prevention ...

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition.

Sanofi has replaced its CEO Paul Hudson after a series of R&D setbacks at the French pharma, handing the reins to Merck KGaA leader Belén Garijo, M.D., Ph.D.

In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO ...

In what is shaping up to be a back-loaded month, the FDA is set to release a slew of regulatory decisions in February, ...

But now, 13 years after the FDA initially blessed it for skin cancer, the U.S. regulator has approved Keytruda as a second- ...

Merck & Co., Inc. extended Keytruda patent protection to 2029; its 40:30:30 strategy and QLEX migration target 18% total returns. See why MRK stock is a buy.

Merck to present data across multiple genitourinary cancers from several approved and investigational medicines at 2026 ASCO GU cancers symposium: Rahway, New Jersey Saturday, Feb ...

Rasha Kelej underscore their commitment to partner with Senegal First Lady to support girl education and build healthcare and media capacity ...